Thymalin

This long-term clinical observation, conducted jointly by the Saint-Petersburg Institute of Bioregulation and Gerontology and the Institute of Gerontology of the Ukrainian Academy of Medical Sciences in Kiev, followed 266 elderly and older persons over a 6–8 year period, with the thymic polypeptide complex Thymalin and the pineal complex Epithalamin administered during the first 2–3 years of observation. The authors reported that the bioregulators were associated with normalization of cardiovascular, endocrine, immune, and nervous system indices, alongside a 2.0–2.4-fold decrease in acute respiratory disease incidence relative to control. The observed mortality rate during follow-up was reduced 2.0–2.1-fold in the Thymalin group, 1.6–1.8-fold in the Epithalamin group, and 2.5-fold in the combination group. A separate subgroup that received Thymalin plus Epithalamin annually for 6 years showed a 4.1-fold reduction in mortality versus control. The paper is indexed in PubMed as a clinical trial. As with all foundational Thymalin literature, this work originates from the Khavinson research lineage, and the trial methodology and outcome adjudication should be evaluated by researchers in that context.

This is the most-cited long-term observational study on Thymalin. Researchers at two institutes in Russia and Ukraine followed 266 elderly people for six to eight years, giving some of them Thymalin (a thymus-derived peptide complex), some of them Epithalamin (a pineal-derived peptide complex), some both, and some nothing. They tracked how often the participants got sick, how their organ systems performed on standard health measures, and how many of them died during the observation window. They reported that the groups receiving the peptide complexes had fewer respiratory infections and lower mortality across the follow-up period. Researchers should weigh this finding against the fact that the work was conducted and published by the same research group that developed Thymalin, and that the published Western literature contains very few independent replications.

This clinical observation evaluated Thymalin as an adjunct to standard inpatient therapy in older patients with severe COVID-19. Patients receiving Thymalin in addition to standard care (n = 36) were compared with a standard-therapy control arm. The authors reported faster recovery from lymphopenia, more rapid normalization of C-reactive protein, and a slower decline in anti-SARS-CoV-2 antibody titers over a 104-day follow-up window (a reported 21% decrease in the Thymalin-plus-standard arm versus 53% in the standard-only arm). The discussion frames Thymalin's reported activity in terms of its low-molecular-weight short-peptide components (notably KE and EW), which the authors describe as binding DNA and histone proteins and modulating the expression of cytokine genes implicated in COVID-19 pathology (IL-1β, IL-6, TNF-α). The study was conducted in Russia outside the FDA regulatory framework, was not blinded, and originates from the same research lineage that developed Thymalin; researchers should weigh those design and provenance factors when evaluating the report.

During the COVID-19 pandemic, the Khavinson group and Russian clinical collaborators looked at whether adding Thymalin to standard hospital care for severe COVID-19 in older patients would change how the immune system responded. They tracked lymphocyte counts (a measure of immune-cell numbers), C-reactive protein (a marker of inflammation), and anti-SARS-CoV-2 antibody levels over more than three months. They reported that the group receiving Thymalin alongside standard care recovered immune-cell counts faster, had inflammation markers come down faster, and held onto their antibody levels longer than the standard-care-only group. Researchers should note that the study was conducted in Russia outside US regulatory oversight, was not a double-blind randomized trial, and was produced by the same research group that developed the peptide complex.